


# UPDATE ON BEST-VALUE MEDICINES FOR TERIPARATIDE



The HSE Medicines Management Programme have identified best-value medicines (BVMs) for teriparatide on the High Tech Arrangement. Prescribing the identified BVMs will lead to significant savings for the health service.

Since 1 March 2023, it is HSE policy that all adult patients who are commencing treatment with teriparatide should be prescribed one of the recommended BVMs for teriparatide.

Since January 2023, there has been a steady increase in the percentage of patients treated with a teriparatide BVM. As of June 2024, 80 percent of the 1,828 patients receiving teriparatide under the High Arrangement are in receipt of an identified BVM product.

**September 2024**

**HSE Medicines Management Programme.**